UBE2B

Across TCGA pan-cancer cohorts, UBE2B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UBE2B data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher UBE2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2B expression acts as an unfavorable survival marker.

LSCC, LUAD, and CCRCC are the cancer types where UBE2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	III,IV	0.537	0.923	.009	15	view →
LUAD	DFS	Tertile	III,IV	0.548	0.875	.040	3	view →
CCRCC	DFS	Median	All	0.588	0.911	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

UBE2B–LSCC (OS)

Open the LSCC breakdown →